Antipsychotics

A new study has found a strong association between antipsychotic drugs and higher rates of severe cases of COVID-19.

Researchers studied whether antipsychotics could prevent transition to full psychosis and found that the drugs worsened outcomes.

A new study published in JAMA Psychiatry connects antipsychotics with damage to the brain in multiple areas.

Psychiatry is now claiming that research has shown that antipsychotics reduce mortality among the seriously mentally ill. A critical review of the literature reveals that this claim is best described as the the field's latest "delusion" about the merits of these drugs.

A new review of antipsychotic trials conducted over the last 24 years finds that the placebo response rate is steadily increasing, and drug response is decreasing.

New research counters the long-held assumption that a longer duration of untreated psychosis is associated with worse outcomes.

A new survey exploring antipsychotic user experience finds that more than half of the participants report only negative experiences.

A new systematic review finds that patients report reduced symptoms but also loss of self and agency while taking antipsychotics.

The FDA recently approved lumateperone for schizophrenia. A review of the clinical trials reveals a testing process that is fatally flawed, and a new drug coming to market that doesn't provide a clinically meaningful benefit.

There is a lack of consensus in the definition of ‘relapse’ across randomized controlled trials of antipsychotic maintenance treatment for schizophrenia and psychosis.

The digital pill Abilify MyCite, which is now being introduced into the market, foretells of a future where such technology is used to monitor the behavior, location and "medication compliance" of a person 24 hours a day.

A new attempt to study the neurological effects of long-term exposure to antipsychotics uses healthy volunteers on minimal doses for 15 days.

New study examines the experiences of people utilizing an exercise program following a first-episode psychosis.

The approval of the digital antipsychotic may open the door for more pharmaceutical company profits without evidence of benefits to patients.

A recently published study from noted critical psychiatry expert Joanna Moncrieff explored the barriers that prevent clinicians from helping service users in discontinuing or...

A study, recently published in Psychological Medicine, examined the cognitive functioning of individuals with schizophrenia who discontinued antipsychotics, and those who maintained their antipsychotic...

People who take anticholinergic drugs, such as antidepressants and antipsychotics, are at a 50% higher risk of dementia.

A new meta-review examines the experiences of antipsychotic drugs use among people diagnosed with a psychotic disorder.

A new study has found that of 10 people who were fully recovered from their first episode of schizophrenia (FES), those not taking antipsychotics did better in terms of cognitive, social, and role functioning—and reached full recovery more quickly.

A new study has found that children and adolescents taking a high dose of antipsychotics are almost twice as likely to die of any cause than children on other types of medications.

Researchers reveal the limitations and misleading interpretations of two recent studies that claim to demonstrate that long-term antipsychotic use leads to better outcomes.

Researchers discuss the evidence that antipsychotic medications may cause brain atrophy in children, whose brains are still developing.

A new analysis of antipsychotic treatment of schizophrenia (published in Schizophrenia Bulletin) has found that two-thirds of patients treated this way do not experience symptom remission.

A systematic review of the limited research available on the long-term effects of antipsychotics finds fewer symptoms in those off of the drugs.

Researchers point to the risks of using antipsychotics with youth and caution against the practice.